TY - JOUR
T1 - Disruption of TP63-miR-27a* feedback loop by mutant TP53 in head and neck cancer
AU - Chari, Nikhil S.
AU - Ivan, Cristina
AU - Le, Xiandong
AU - Li, Jinzhong
AU - Mijiti, Ainiwaer
AU - Patel, Ameeta A.
AU - Osman, Abdullah A.
AU - Peterson, Christine B.
AU - Williams, Michelle D.
AU - Pickering, Curtis R.
AU - Caulin, Carlos
AU - Myers, Jeffrey N.
AU - Calin, George A.
AU - Lai, Stephen Y.
N1 - Funding Information: This work was partially supported by grants from the Brandon C. Gromada Head and Neck Cancer Foundation, Elsa U. Pardee Foundation, Institutional Startup Funds, and The University of Texas MD Anderson Cancer Center-Oropharynx Cancer Program generously supported by Mr and Mrs Charles W. Stiefel awarded to SYL. This work was supported in part by National Institutes of Health/National Cancer Institute Cancer Center Support Grant grant P30CA016672, including CBP (Biostatistics Shared Resource). Publisher Copyright: © The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: [email protected].
PY - 2021
Y1 - 2021
N2 - Background: Alterations in the epidermal growth factor receptor and PI3K pathways in head and neck squamous cell carcinomas (HNSCCs) are frequent events that promote tumor progression. Ectopic expression of the epidermal growth factor receptor-targeting microRNA (miR), miR-27a* (miR-27a-5p), inhibits tumor growth. We sought to identify mechanisms mediating repression of miR-27a* in HNSCC, which have not been previously identified. Methods: We quantified miR-27a* in 47 oral cavity squamous cell carcinoma patient samples along with analysis of miR-27a* in 73 oropharyngeal and 66 human papillomavirus-positive (HPVþ) samples from The Cancer Genome Atlas. In vivo and in vitro TP53 models engineered to express mutant TP53, along with promoter analysis using chromatin immunoprecipitation and luciferase assays, were used to identify the role of TP53 and TP63 in miR-27a* transcription. An HNSCC cell line engineered to conditionally express miR-27a* was used in vitro to determine effects of miR-27a* on target genes and tumor cells. Results: miR-27a* expression was repressed in 47 oral cavity tumor samples vs matched normal tissue (mean log2 difference ¼ -0.023, 95% confidence interval ¼ -0.044 to -0.002; two-sided paired t test, P ¼.03), and low miR-27a* levels were associated with poor survival in HPVþ and oropharyngeal HNSCC samples. Binding of DNp63a to the promoter led to an upregulation of miR-27a*. In vitro and in vivo findings showed that mutant TP53 represses the miR-27a* promoter, downregulating miR-27a* levels. DNp63a and nucleoporin 62, a protein involved in DNP63a transport, were validated as novel targets of miR-27a*. Conclusion: Our results characterize a negative feedback loop between TP63 and miR-27a*. Genetic alterations in TP53, a frequent event in HNSCC, disrupt this regulatory loop by repressing miR-27a* expression, promoting tumor survival.
AB - Background: Alterations in the epidermal growth factor receptor and PI3K pathways in head and neck squamous cell carcinomas (HNSCCs) are frequent events that promote tumor progression. Ectopic expression of the epidermal growth factor receptor-targeting microRNA (miR), miR-27a* (miR-27a-5p), inhibits tumor growth. We sought to identify mechanisms mediating repression of miR-27a* in HNSCC, which have not been previously identified. Methods: We quantified miR-27a* in 47 oral cavity squamous cell carcinoma patient samples along with analysis of miR-27a* in 73 oropharyngeal and 66 human papillomavirus-positive (HPVþ) samples from The Cancer Genome Atlas. In vivo and in vitro TP53 models engineered to express mutant TP53, along with promoter analysis using chromatin immunoprecipitation and luciferase assays, were used to identify the role of TP53 and TP63 in miR-27a* transcription. An HNSCC cell line engineered to conditionally express miR-27a* was used in vitro to determine effects of miR-27a* on target genes and tumor cells. Results: miR-27a* expression was repressed in 47 oral cavity tumor samples vs matched normal tissue (mean log2 difference ¼ -0.023, 95% confidence interval ¼ -0.044 to -0.002; two-sided paired t test, P ¼.03), and low miR-27a* levels were associated with poor survival in HPVþ and oropharyngeal HNSCC samples. Binding of DNp63a to the promoter led to an upregulation of miR-27a*. In vitro and in vivo findings showed that mutant TP53 represses the miR-27a* promoter, downregulating miR-27a* levels. DNp63a and nucleoporin 62, a protein involved in DNP63a transport, were validated as novel targets of miR-27a*. Conclusion: Our results characterize a negative feedback loop between TP63 and miR-27a*. Genetic alterations in TP53, a frequent event in HNSCC, disrupt this regulatory loop by repressing miR-27a* expression, promoting tumor survival.
UR - http://www.scopus.com/inward/record.url?scp=85082147291&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082147291&partnerID=8YFLogxK
U2 - 10.1093/JNCI/DJZ097
DO - 10.1093/JNCI/DJZ097
M3 - Article
C2 - 31124563
SN - 0027-8874
VL - 112
SP - 266
EP - 277
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 3
M1 - DJZ097
ER -